Clinical dilemmas in inflammatory bowel disease: new challenges

ÍNDICE: List of Contributors. Preface. Part 1: Genes and Phenotype in IBD. 1 Which will take us further in IBD study of coding variation or epigenetics? (Miles Parkes). 2 IBD in different ethnic groups: same or different? (Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger). Part 2: Bugs and IBD good, bad or indifferent? 3 How does the risk of infection influence management of IBD around the world? (Kiran K. Peddi and Ian Craig Lawrance). 4 Travelling with IBD (Ing Shian Soon and Gilaad Kaplan). 5 What to do about hepatitis Band hepatitis C in patients with IBD (Morven Cunningham and Graham R. Foster). 6 CMV in IBD passenger or pathogen? (Ahmed Kandiel light at the end of theirburrow? (John Leung and Joel V. Weinstock). 10 Do we really need to vaccinateall patients with IBD? (Gauree Gupta and Gil Y. Melmed). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel? (Richard B. Gearry, Andrew S. Day). 12 Radiation exposure in IBD: how do we minimize the dangers? (Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher). 13 Surveillance colonoscopy in UC whats the best way to do it? (Matt Rutter). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride forward? (L. CampbellLevy). 15 Do 5ASAs prevent cancer? (Richard Logan and Venkataraman Subramanian). 16 Why do we still use 5-ASAs in Crohns disease? (Stephen Hanauer, Henit Yanai, Emma Calabrese). Steroids. 17 Steroids in Crohn's disease: do the benefits outweigh the dangers? (A. Hillary Steinhart). Immunomodulators. 18 Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or resistant? (Miles Sparrow). 19 Thiopurines and the sun: what should be done? (Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood). 20 Do thiopurines worsen risk and prognosis of cervical neoplasia? (Jeremy D. Sanderson and Melissa A. Smith). 21 Optimising use of methotrexate (Anna Foley and Peter R. Gibson). 22 Whichcalcineurin inhibitor and when? (A. Barney Hawthorne). Biologics. 23 Are all anti-TNF agents the same? (Jennifer L. Jones). 24 One drug or two: Do patientson biologics need concurrent immunomodulation? (Glen A. Doherty and Adam S. Cheifetz). 25 How do we identify patients needing early aggressive therapy and what should we use? (Marc Ferrante and Séverine Vermeire). 26 What is the roleof biologics in UC? (Joanna K. Law and Brian Bressler). 27 What can we do with Crohn's patients refractory to antiTNF therapy? (David T. Rubin). 28 Which EIMs respond to biologics? (Tina A. Mehta and CS Probert). 29 Use and abuse of biologics in pregnancy (Marla C. Dubinsky). 30 Is anti-TNF therapy safe to usein people with a history of malignancy? (Mark Lust and Simon Travis). 31 Whatand how should we tell patients about the risks of immunomodulators and biologics? (Corey A Siegel). 32 When, how and in whom should we stop biologics? (Edouard Louis, Jacques Belaiche, Catherine Reenaers). Part 5: Other treatments. 33 Avoiding drug interactions (Tim Elliott and

• ISBN: 978-1-4443-3454-8
• Editorial: Wiley-Blackwell
• Encuadernacion: Rústica
• Páginas: 268
• Fecha Publicación: 12/08/2011
• Nº Volúmenes: 1
• Idioma: Inglés